Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Non-Current Assets of $623.1 million for Q1 2026, down 3.82% on a QoQ basis from $647.9 million in Q4 2025, and down 14.52% year-over-year from $728.9 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Non-Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Non-Current Assets history runs 7 years deep, the most recent figure standing at $623.1 million for Q1 2026.
- Quarterly Non-Current Assets fell 14.52% year-over-year to $623.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (down 15.86% YoY) and the FY2025 annual result came in at $647.9 million, down 16.37% from the prior year.
- Non-Current Assets was $623.1 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $647.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.1 billion in Q1 2023 and bottomed at $351.9 million in Q1 2022.
- A 5-year average of $732.7 million and a median of $708.0 million in 2025 frame the typical range for Non-Current Assets.
- Peak annual rise in Non-Current Assets reached 213.05% in 2022, while the deepest fall reached 79.6% in 2022.
- Ginkgo Bioworks Holdings' Non-Current Assets stood at $1.1 billion in 2022, then slumped by 39.08% to $663.6 million in 2023, then rose by 16.74% to $774.7 million in 2024, then declined by 16.37% to $647.9 million in 2025, then declined by 3.82% to $623.1 million in 2026.
- Business Quant data shows DNA's Non-Current Assets at $623.1 million in Q1 2026, $647.9 million in Q4 2025, and $683.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | 623.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 623.12 Mn |
| Dec 31, 2025 | 647.86 Mn |
| Sep 30, 2025 | 683.08 Mn |
| Jun 30, 2025 | 707.98 Mn |
| Mar 31, 2025 | 728.93 Mn |
| Dec 31, 2024 | 774.71 Mn |
| Sep 30, 2024 | 818.40 Mn |
| Jun 30, 2024 | 841.89 Mn |
| Mar 31, 2024 | 678.74 Mn |
| Dec 31, 2023 | 663.59 Mn |
| Sep 30, 2023 | 884.55 Mn |
| Jun 30, 2023 | 1.07 Bn |
| Mar 31, 2023 | 1.09 Bn |
| Dec 31, 2022 | 1.09 Bn |
| Sep 30, 2022 | 408.69 Mn |
| Jun 30, 2022 | 395.37 Mn |
| Mar 31, 2022 | 351.89 Mn |
| Dec 31, 2021 | 347.95 Mn |
| Sep 30, 2021 | 340.02 Mn |
| Jun 30, 2021 | 1.73 Bn |